StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Abacavir

HCID 441300
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
136470-78-5
Standard-SMILES
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1
InChIKey
MCGSCOLBFJQGHM-SCZZXKLOSA-N
Summenformel
C14H18N6O
Durchschnittliche Molmasse
286,33 g/mol
Monoisotopische Masse
286,15420922

Überblick

Abacavir is a 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. It has a role as an antiviral drug, a HIV-1 reverse transcriptase inhibitor and a drug allergen.

Namen und Bezeichner

Bevorzugter Name
Abacavir
IUPAC
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
Englischer Name
Abacavir
Summenformel
C14H18N6O
Molmasse
286.33

Namen und Synonyme

abacavir136470-78-5(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol((1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methanolAvacavirWR2TIP26VSDTXSID4046444CHEBI:4217072-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)-NSC-742406[(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol[(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1-cyclopent-2-enyl]methanol
Weitere Namen anzeigen
CS-1071592u89Abacavir >Abacavir(base)Abacavir TabletAbacavir, ≥ 98.0%Abacavir USP/EP/BPAbacavir StandardAbacavir - Bio-X ?
{(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-(-)-CIS-4-(2-AMINO-6-(CYCLOPROPYLAMINO)-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL(1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S,4R)-abacavirum((1S,4R)-4-(2-amino-6-(cyclopropylamino)purin-9-yl)-1-cyclopent-2-enyl)methanol

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,9
Polarare Oberfläche (TPSA)
102 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
4
Schwere Atome
21
Formalladung
0
Komplexität
414

Experimentelle und physikochemische Eigenschaften

Chemical ClassesPharmaceutical
Drugs · 2 Einträge

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Listed in ZINC15

LogP1.1
Solubility1.21e+00 g/L
Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Reverse Transcriptase Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Melting Point165 °C
Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (87.5%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P272, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P333+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (87.5%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Elevations in serum aminotransferase levels above 5 times the upper limit of normal occur in up to 6% of patients on abacavir. These elevations are usually mild, transient and do not require dose adjustment. Clinically apparent hepatotoxicity is rare, but isolated cases [usually anicteric] have been published. The liver injury usually arises in the context of abacavir hypersensitivity syndrome and may be overshadowed by the allergic syndromes of fever, rash and fatigue. The onset is usually within 1 to 3 months of starting abacavir. The serum enzyme pattern can be hepatocellular or cholestatic. Patients typically recover rapidly within 4 weeks of stopping therapy.

Adverse Effects · 1 Eintrag

The common toxicities of the NRTI class include mitochondrial toxicity, which can present as hepatic steatosis, lipoatrophy, pancreatitis, and peripheral neuropathy. Symptomatic lactic acidosis can also occur, and these patients require monitoring due to an increased risk of mortality. Long-term antiretroviral therapy (ART) patients may experience fat redistribution, also known as lipodystrophy. Clinicians should avoid abacavir in patients with coronary artery disease and those at increased risk of myocardial infarction due to an increased risk of hyperlipidemia and cardiovascular events.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

J05AF06

Protein BindingModerate (approximately 50%). Binding of abacavir to plasma protein was independent of concentration.
Pharmacodynamics · 1 Eintrag

Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The concentration of drug necessary to effect viral replication by 50 percent (EC50) ranged from 3.7 to 5.8 μM (1 μM = 0.28 mcg/mL) and 0.07 to 1.0 μM against HIV-1IIIB and HIV-1BaL, respectively, and was 0.26 ± 0.18 μM against 8 clinical isolates. Abacavir had synergistic activity in cell culture in combination with the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, and the protease inhibitor (PI) amprenavir; and additive activity in combination with the NRTIs didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine.

Mechanism of Action · 1 Eintrag

Abacavir is a carbocyclic synthetic nucleoside analogue and an antiviral agent. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Viral DNA growth is terminated because the incorporated nucleotide lacks a 3'-OH group, which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation.

Biological Half-Life1.54 ± 0.63 hours
Metabolism/Metabolites · 1 Eintrag

Hepatic, by alcohol dehydrogenase and glucuronosyltransferase to a 5′-carboxylic acid metabolite and 5′-glucuronide metabolite, respectively. These metabolites have no antiviral activity. Abacavir is not significantly metabolized by cytochrome P450 enzymes.

Zugehörige Reaktionen

11
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 420887
HRID 420887als Produkt
Reaktionsgleichung von HRID 1087040
HRID 1087040als Produkt
Reaktionsgleichung von HRID 1417009
HRID 1417009als Produkt
Reaktionsgleichung von HRID 1534400
HRID 1534400als Produkt
Reaktionsgleichung von HRID 1591416
HRID 1591416als Produkt
Reaktionsgleichung von HRID 1928523
HRID 1928523als Produkt
Reaktionsgleichung von HRID 1928524
HRID 1928524als Produkt
Reaktionsgleichung von HRID 1928525
HRID 1928525als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
136470-78-5
PubChem CID
441300
DTXSID
DTXSID4046444
ChEMBL
CHEMBL1380
ChEBI
CHEBI:421707
UNII
WR2TIP26VS
EC Number
620-487-9
Nikkaji
J825.172J
165 ° · 165°
Siedepunkt
636 · 636.0±65.0 °C(Predicted)
Dichte
1.7 · 1.70±0.1 g/cm3(Predicted)
storage temp.
2 · Sealed in dry,2-8°C
Löslichkeit
DMSO (Slightly, Heated), Methanol (Slightly)
pka
5.01 · 5.01(at 25℃)
Aggregatzustand
Solid
Farbe
Off-White to Pale Beige
Merck
14 · 14,1
BCS Class
3 · 3
CAS Datenbank
136470 · 136470-78-5(CAS DataBase Reference)
EPA chemische Informationen
2 · 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)- (136470-78-5)
Toxicity Summary · 1 Eintrag

Severe and sometimes fatal hypersensitivity reactions can potentially occur with abacavir. Patients with the HLA-B*5701 allele also carry a higher risk for a hypersensitivity reaction to abacavir; hypersensitivity reactions have occurred in those who do not test positive for the HLA-B*5701 allele. All patients should receive screening for the HLA-B*5701 allele.

Drug Induced Liver Injury · 6 Einträge

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

abacavir

Ziagen®

Antivirals

8

most-DILI-concern

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
USGS Health-Based Screening Levels for Evaluating Water-Quality · 3 Einträge

Abacavir

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Abacavir

14.0

59.2

The recommended dosage of abacavir tablets for adults is 600 mg daily.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 600 mg/day, Lowest Therapeutic Dose (LTD): 7.5 mg/kg-day, and Screening Dose: 0.003 mg/kg-day.

8-Jan-21

Sicherheitsdaten

hs_code
2933.99.7500
RTECS-Nr.
GY5979200
FDA Pharmacological Classification · 6 Einträge

WR2TIP26VS

ABACAVIR

Established Pharmacologic Class [EPC] - Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Mechanisms of Action [MoA] - Nucleoside Reverse Transcriptase Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 1A1 Inhibitors

Abacavir is a Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor. The mechanism of action of abacavir is as a Nucleoside Reverse Transcriptase Inhibitor and Cytochrome P450 1A1 Inhibitor.

Absorption, Distribution and Excretion · 4 Einträge

Rapid and extensive after oral administration (83% bioavailability, tablet). When a 300 mg tablet is given twice daily to subjects, the peak plasma concentration (Cmax) was 3.0 ± 0.89 mcg/mL and the area under the curve (AUC 0-12 hours) was 6.02 ± 1.73 mcg•hr/mL.

Elimination of abacavir was quantified in a mass balance study following administration of a 600-mg dose of 14C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose. Renal excretion of unchanged abacavir is a minor route of elimination in humans.

0.86 ± 0.15 L/kg [IV administration]

0.80 ± 0.24 L/hr/kg [asymptomatic, HIV-1-infected adult patients receiving single (IV dose of 150 mg]

Cellular LocationsCytoplasm
Metabolite PathwaysAbacavir Action Pathway

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >500
Anwendungen · 2 Einträge

BeschreibungThe drug is extensively metabolized via stepwise phosphorylation to 5′-mono-, di-, and triphosphate. Abacavir is well absorbed (>75%) and penetrates the CNS. The drug can be taken without regard to meals. The drug does not show any clinically significant drug–drug interactions. Abacavir has been reported to produce life-threatening hypersensitivity reactions. The major use of abacavir appears to be in combination with other nucleoside RT inhibitors. A fixed-combination product has recently been approved by the U.S. FDA consisting of 300 mg of ABC, 150 mg of 3TC, and 300 mg of ZDV (Trizivar). The combination has been shown to be superior to other combinations in reducing viral load as well as to show improvement in CD4 cell count.

VerwendenAbacavir is a commonly used nucleoside analogue with potent antiviral activity against HIV-1. - See more at: http://www.selleckchem.com/products/abacavir-sulfate.html#sthash.lApvcTNO.dpuf

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

DibenzoateDibenzoyltartaric acid(1S-cis)-4-Amino-2-cyclopentene-1-methanol(Chloromethylene)dimethyliminium chloride2,5-Diamino-4,6-dihydroxy-pyrimidine2,5-Diamino-4,6-dihydroxypyrimidine hydrochloride2-Amino-6-hydroxy-1H-pyrimidin-4-onCyclopropylaminN,N-Diethylethanamin(+)-Weinsure